ORGO Q3 2019 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena

ORGOOrganogenesis Holdings Inc.

$338M

Q3 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$64M

Gross Profit

$45M70.2% margin

Operating Income

-$8M-12.9% margin

Net Income

-$11M-16.7% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

-1.1%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$7M

Stock-Based Comp.

$242,000

Balance Sheet

Total Assets

$175M

Total Liabilities

$162M

Stockholders' Equity

$13M

Cash & Equivalents

$23M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$64M	$0	—
Gross Profit	$45M	-$2M	+2106.9%
Operating Income	-$8M	-$2M	-267.5%
Net Income	-$11M	$5M	-317.6%

Revenue Segments

Advanced Wound care

$54M85%

Surgical and Sports Medicine

$10M15%